Genmab — November 2018
-
Spørgeren refererer til "i hvert fald de sidste 5 kvartaler". Tror i øvrigt peter12 har ret i at der refereres til IMS-tal. Og da tallet i US 2107Q1 var 201M og i 2018Q2 (har ikke lige 2018Q3: hvad var IMS tallet for september?) var 346, passer det jo fint med hans læsning som 25M$/kvartal.
-
Nogen skal spørge ham på onsdag om den "endnu hurtigere godkendelse" - hvad er det mere præcist han refererer til (udover den altid omskiftelige Trumps slyngen om sig med forsikringer om dette og hint (som alle medier jo tilsyneladende har glemt 5 dage senere))?
-
Er det ikke breakthrough designation han håber på? https://www.fda.gov/forpatients/approvals/fast/default.htm
-
-
Det mener jeg. A drug that receives Breakthrough Therapy designation is eligible for the following:
All Fast Track designation features
Intensive guidance on an efficient drug development program, beginning as early as Phase 1
Organizational commitment involving senior managers
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind